Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480746 | 0.98 | LMNA (0.43) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL11472255 | 0.91 | ALDH1A1 (0.48) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL2098448 | 0.91 | ALDH1A1 (0.54) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL3073339 | 0.85 | — | — | |
| SCHEMBL4072646 | 0.83 | LMNA (0.48) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL11088981 | 0.83 | LMNA (0.38) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL11087712 | 0.83 | LMNA (0.38) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL11197727 | 0.81 | LMNA (0.46) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL1070729 | 0.79 | — | — | |
| SCHEMBL902387 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664046-B1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7462721-B2 | Aza-quinolinol phosphonate integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | GILEAD SCIENCES, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | JIN HAOLUN | 2007-08-09 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1711476-A2 | PYRIMIDYL PHOSPHONATE ANTIVIRAL COMPOUNDS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1664046-A1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20050282839-A1 | Pyrimidyl phosphonate antiviral compounds and methods of use | GILEAD SCIENCES, INC. | 2005-12-22 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005070901-A2 | PYRIMIDYL PHOSPHONATE ANTIVIRAL COMPOUNDS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20050137199-A1 | Inhibition of HiV integrase compounds | GILEAD SCIENCES, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005028478-A1 | AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040097562-A1 | Method for treating tension-type headache | HEAD EXPLORER APS (DK) | 2004-05-20 | — | — | US | disclosed |
| EP-0010366-B1 | SOLID ORGANOMETALLIC INORGANIC POLYMERS AND THEIR APPLICATION | OCCIDENTAL RESEARCH CORPORATION (US) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153783-A1 | Pyrimidyl Phosphonate Antiviral Compounds and Methods of Use | TYMP, MTAP, PNP | LMNA 3062/4885SLC22A6 3925/4885TSHR 4483/4885 |
| US-20050137199-A1 | Inhibition of HiV integrase compounds | CDKL5, CDKL1, CDKL3 | LMNA 680/4885SLC22A6 4176/4885TSHR 4115/4885 |
| US-20050282839-A1 | Pyrimidyl phosphonate antiviral compounds and methods of use | TYMP, MTAP, PNP | LMNA 3062/4885SLC22A6 3925/4885TSHR 4483/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | LMNA 2126/4885SLC22A6 3268/4885TSHR 4778/4885 |
| US-20070185007-A1 | Aza-quinolinol phosphonate integrase inhibitor compounds | CDKL5, CDKL1, CDKL3 | LMNA 1002/4885SLC22A6 3846/4885TSHR 3990/4885 |
| US-20040097562-A1 | Method for treating tension-type headache | GRIN3A, GRIN2A, GRIK4 | LMNA 2602/4885SLC22A6 1768/4885TSHR 1186/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | LMNA 2126/4885SLC22A6 3268/4885TSHR 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.